


# Figure S1



**Figure S1.** A. Alignment of the complex structure of ZL-1201/CD47 and 5F9/CD47 complex (PDB 5IWL). Green: 5F9 diabody, cyan: ZL-1201 Fab. B. ZL-1201 and 5F9 prevents SIRP $\alpha$  binding to Raji cells in a dose-dependent manner. C and D. In vitro binding of isotype control, benchmark, and ZL-1201 with HCC1954 (C), and Raji (D) cells in a dose-dependent manner. E. In vitro binding of isotype control, ZL-1201-Fc-WT, and ZL-1201 with Raji cells in a dose-dependent manner. F and G. In vitro binding of isotype control, benchmark, and ZL-1201 with human red blood cells (RBC) (F) and platelets (G) in a dose-dependent manner. H. Hemagglutination assay of benchmark and ZL-1201 in dose dependent manner. Data are representative of two independent experiments. I-K. Binding of ZL-1201 to cynomolgus monkey RBCs (I), WBCs (J), and whole blood cells (K) (n = 3) in a dose-dependent manner. HuIgG4 isotype was used as a negative control at 1.34 $\mu$ M.